medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2019, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2019; 64 (4)

Efficacy of intralesional cidofovir for the treatment of juvenile recurrent respiratory papillomatosis: a systematic review

Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Bross-Soriano D, Cano-Salas MC, Garrido-Galindo C, Ruiz-Cruz M, Schimelmitz-Idi J

Language: Spanish
References: 42
Page: 270-276
PDF size: 240.54 Kb.


ABSTRACT

Background: Juvenile recurrent respiratory papillomatosis is a chronic disease of viral etiology that usually requires repeated surgical interventions in order to avoid respiratory obstruction an improve voice quality. There is no treatment to cure the disease. However, intralesional cidofovir is the most common adjuvant therapy. Objective: The objective of this study was to systematically review current evidence of the efficacy of intralesional cidofovir for the treatment of juvenile recurrent respiratory papillomatosis. Methods: The search strategy included the data bases of Cochrane Library, PubMed, EMBASE, LILACS, SciELO, TripDatabase, National Guidelines Clearinghouse and ClinicalTrials.gov. We included randomized and non-randomized controlled clinical trials, cohort studies, case-control studies, case series and case reports. Published studies until February 23, 2019 were considered. Results: We found a total of 91 references. Of these, 69 were eliminated in the first screening after reading the abstracts. The 22 remaining studies were assessed with STROBE and CONSORT. Only 13 studies were selected for the classification of evidence with GRADE. Because evidence was of low-quality, all studies were eliminated. No studies were included in the final analysis. It was not possible to perform a meta-analysis from this systematic review. Conclusions: We did not find high-quality evidence of the efficacy of intralesional cidofovir for the treatment of juvenile recurrent respiratory papillomatosis. Large, double-blind, placebo controlled, randomized trials are required to support the efficacy of cidofovir for the treatment of juvenile recurrent respiratory papillomatosis. It is likely that a multi-center trial will be required to enroll adequate patient numbers.


REFERENCES

  1. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010; 118: 450-454.

  2. Steinberg BM, DiLorenzo TP. A possible role for human papillomaviruses in head and neck cancer. Cancer Metastasis Rev. 1996; 15: 91-112.

  3. Dickens P, Srivastava G, Loke SL, Larkin S. Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J Pathol. 1991; 165: 243-246.

  4. Xue Q, Wang H, Wang J. Recurrent respiratory papillomatosis: an overview. Eur J Clin Microbiol Infect Dis. 2010; 29 (9): 1051-1054.

  5. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995; 121 (12): 1386-1391.

  6. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999; 125: 743-748.

  7. Omland T, Akre H, Lie KA, Jebsen P, Sandvik L, Brřndbo K. Risk factors for aggressive recurrent respiratory papillomatosis in adults and juveniles. PLoS One. 2014; 9 (11): e113584.

  8. Hermann JS, Pontes P, Weckx LL, Fujita R, Avelino M, Pignatari SS. Laryngeal sequelae of recurrent respiratory papillomatosis surgery in children. Rev Assoc Med Bras (1992). 2012; 58 (2): 204-208.

  9. Katsenos S, Becker HD. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol. 2011; 4: 162-171.

  10. FDA Approved Drug Products. Vistide. [Consultado 8/abril/2019]. Disponible en: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020638.

  11. Tjon Pian Gi RE, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®). Eur Arch Otorhinolaryngol. 2012; 269 (2): 361-362.

  12. Broekema FI, Dikkers FG. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008; 265: 871-879.

  13. Carifi M, Napolitano D, Morandi M, Dall’Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015; 11:731-38.

  14. Schulz KF, Altman DG, Moher D, the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340: 698-702.

  15. von Elm E, Altman DG, Egger M, Pocock SJ, Gřtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61: 344-349.

  16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-926.

  17. McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol. 2008; 117: 477-483.

  18. Ablanedo-Terrazas Y, Soda-Merhy A, Hernández-Palestina M, Ormsby CE, Reyes-Terán G. Intralesional cidofovir in severe juvenile respiratory papillomatosis. B-ENT. 2012; 83: 197-202.

  19. Graupp M, Gugatschka M, Kiesler K, Reckenzaun E, Hammer G, Friedrich G. Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2013; 270: 641-646.

  20. Valera F, Maldonato L, Lima J, Küpper DS, Lacerda RN, Mamede R et al. Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis. Braz J Otorhinolaryngol. 2010; 76: 713-717.

  21. Bielecki I, Mniszek J, Cofała M. Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol. 2009; 73: 681-684.

  22. Shi ZP, Wang CH, Lee JC, Lin YS. Cidofovir injection for recurrent laryngeal papillomatosis. J Chin Med Assoc. 2008; 71: 143-146.

  23. Pudszuhn A, Welzel C, Bloching M, Neumann K. Intralesional cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Otorhinolaryngol. 2007; 264: 63-70.

  24. Naiman AN, Ayari S, Nicollas R, Landry G, Colombeau B, Froehlich P. Intermediate-term and long-term results after treatment by cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol. 2006; 115: 667-672.

  25. Chung BJ, Akst LM, Koltai PJ. 3.5-year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2006; 70: 1911-1917.

  26. Sheahan P, Sexton S, Russell JD. Is intralesional cidofovir worthwhile in juvenile recurrent respiratory papillomatosis? J Laryngol Otol. 2006; 120: 561-565.

  27. Lee AS, Rosen CA. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J Voice. 2004; 18: 551-556.

  28. Peyton-Shirley W, Wiatrak B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol. 2004; 68: 413-418.

  29. Naiman AN, Ceruse P, Coulombeau B, Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope. 2003; 113: 2174-2181.

  30. Chhetri DK, Shapiro NL. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg. 2003; 129: 1081-1085.

  31. Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope. 2003; 113: 1583-1587.

  32. Akst LM, Lee W, Discolo C, Knott D, Younes A, Koltai PJ. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg. 2003; 129: 841-846.

  33. Milczuk HA. Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children. Otolaryngol Head Neck Surg. 2003; 128: 788-794.

  34. El Hakim H, Waddell AN, Crysdale WS. Observations on the early results of treatment of recurrent respiratory papillomatosis using cidofovir. J Otolaryngol. 2002; 31: 333-335.

  35. Pransky SM, Brewster DF, Magit AE, Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000; 126: 1239-1243.

  36. Mandell DL, Arjmand EM, Kay DJ, Casselbrant ML, Rosen CA. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2004; 130: 1319-11323.

  37. Durvasula VS, Richter GT. Intralesional cidofovir as adjuvant for the successful management of aggressive respiratory papillomatosis in an infant. Int J Pediatr Otorhinolaryngol. 2013; 77: 1912-1915.

  38. Palomar-Asenjo V, Palomar-García V, Soteras-Ollé J, Ruiz-Giner A. Cidofovir activity in infantile recurrent respiratory papillomatosis. Acta Otorrinolaringol Esp. 2005; 56: 22-24.

  39. Clamp PJ, Saunders MW. Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2013; 77 (3): 323-328.

  40. Drejet S, Halum S, Brigger M, Skopelja E, Parker N. A systematic review: outcomes in adult recurrent respiratory papillomatosis treated with intralesional cidofovir or bevacizumab. Otolaryngol Head Neck Surg. 2017; 156 (3): 435-441.

  41. Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg. 2007; 136 (6): 863-869.

  42. Chadha NK. Intralesional cidofovir for recurrent respiratory papillomatosis: Systematic review of efficacy and safety. J Laryngol Voice. 2011; 1: 22-26.




2020     |     www.medigraphic.com